Anixa Biosciences Announces Japanese Patent On Ovarian Cancer Vaccine Technology
Portfolio Pulse from Benzinga Newsdesk
Anixa Biosciences, Inc. (NASDAQ:ANIX) announced that its collaborator, Cleveland Clinic, received a 'Decision to Grant' notice from the Japan Patent Office for an ovarian cancer vaccine patent. This extends the geographic coverage of the patent, which already includes Europe and the U.S. The vaccine technology, exclusively licensed by Anixa, showed pre-clinical promise in preventing epithelial ovarian carcinoma. The research is supported by the National Cancer Institute's PREVENT Program.
January 23, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Anixa Biosciences received a patent grant in Japan for its ovarian cancer vaccine, adding to its existing U.S. and European patents. The vaccine has shown pre-clinical efficacy in preventing epithelial ovarian carcinoma.
The grant of the Japanese patent is likely to have a positive impact on Anixa Biosciences' stock in the short term. It strengthens the company's intellectual property position and potential market reach for its ovarian cancer vaccine. Investors may view this as a positive development, as it could lead to future revenue streams and partnerships in the Japanese market. The importance is high due to the potential of the vaccine to prevent a common and aggressive cancer, but not at the maximum since it is still in the pre-clinical phase. The confidence level is high due to the clear positive nature of the news, but not at 100% because the market's reaction can be unpredictable.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100